The Aesthetics Advisor

Medically Reviewed by: Dr. Frank Yap, MD | Written by: OneDayMD Editorial Team | Published: March 2026 | Last updated: October 6, 2026 Quick Answer As of October 2026, tirzepatide (Zepbound) is the strongest FDA-approved option at about 20–21% average weight loss, ahead of semaglutide (Wegovy) at about 15% (20.7% at the new 7.2 mg dose). Retatrutide, a triple agonist, reached 28.3% at 80 weeks in Phase 3 but is not FDA-approved ; Lilly plans to file in Q1 2027. What changed in this update (Oct 2026): replaced pre-Phase-3 estimates with TRIUMPH-1/2/3 results; corrected retatrutide launch timing (not before late 2027); added Wegovy HD, the Wegovy pill, Foundayo and CagriSema context; removed claims sourced only from research-peptide vendors, forum posts and unverified preprints; added CEBM evidence tiers, FAQ and an AI-prompt guide. Contents At-a-glance comparison How the three work What the trials show (and don't) Retatrutide: status in October 2026 Muscle and lean...

Quick Summary of Key Insights "Ozempic Face" is a result of rapid weight loss, not the drug itself. Up to 35-40% of weight lost can come from lean mass if not managed carefully. Gradual weight loss (1-2 pounds per week) is the gold standard for skin and muscle protection. Protein and resistance training are non-negotiable for preserving metabolic health. Glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have revolutionized the treatment of obesity and type 2 diabetes. While these medications offer unprecedented weight loss efficacy, they also bring unique aesthetic and physiological challenges that require proactive management. Demystifying "Ozempic Face" The term "Ozempic Face" refers to the gauntness, sunken cheeks, and increased wrinkles that can appear during rapid weight loss. This occurs ...